Loading clinical trials...
Loading clinical trials...
An Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
Conditions
Interventions
Rivaroxaban 15 mg
Locations
1
United States
Knoxville, Tennessee, United States
Start Date
January 1, 2015
Primary Completion Date
March 1, 2015
Completion Date
March 1, 2015
Last Updated
January 24, 2017
NCT04634916
NCT06933472
NCT07224763
NCT07033260
NCT05738525
NCT06373575
Lead Sponsor
Janssen Research & Development, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions